Please login to the form below

Not currently logged in
Email:
Password:

Bayer promotes Robert LaCaze

He becomes EVP of new oncology strategic business unit

Leverkusen, Germany-based Bayer has promoted Robert LaCaze to executive vice president of its new oncology strategic business unit, part of the firm's pharmaceutical division.

LaCaze joins the pharmaceutical division's executive committee, and will be responsible for implementing the new unit's accelerated development model for new oncology therapies.

He first joined Bayer in 2015 and most recently served as senior vice president and head of global oncology therapeutic area at the firm.

Prior to this, LaCaze spent 27 years at Bristol-Myers Squibb, holding a series of increasingly senior oncology-focused managerial roles, before becoming senior vice president and head of product and portfolio strategy at Bristol-Myers Squibb in 2014.

Dieter Weinand, head of the Bayer Pharmaceutical executive committee, said: “We are delighted to have an executive with Robert LaCaze's experience and talent lead the Oncology Strategic Business Unit.

“I am confident that he will contribute his expertise and foresight to help strengthen our efforts in the fight against cancer.”

9th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Anthill_icon_Green_17_Multi-channel.png
Can you access your own content?
The rapid development of multichannel communication opens new opportunities to provide high-value experiences for healthcare professionals and gives you more places than ever to tell your product story. But unless...
How will capitated budgets affect NHS spending?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the implications of a single budget covering all the physical, mental and social care needs of patients in an STP...
Dissecting adherence to personalise patient support
Across the healthcare and pharmaceutical industries, the initiatives to better understand the patient journey and lower healthcare costs have been growing in magnitude. One solution that has repeatedly been raised...

Infographics